| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2023年期初占 | 2023年度占用 | 2023 年度占 | 2023 年度偿 | 2023 年期末 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 用资金余额 | 累计发生金额 | 用资金的利 | 还累计发生 | 占用资金余 | 因 | | | | | | | | （不含利息） | 息(如有) | 金额 | 额 | | | | 控股股东、实际控制人 | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 其他关联方及附属企 | ...

Financial Performance - The company's revenue for the first half of 2023 reached ¥846,347,925.21, representing a 56.68% increase compared to ¥540,171,731.25 in the same period last year[20]. - The net profit attributable to shareholders for the reporting period was ¥135,286,640.78, up 63.44% from ¥82,777,022.64 in the previous year[20]. - Basic earnings per share rose to ¥0.1293, a 63.46% increase from ¥0.0791 in the previous year[20]. - The company reported a significant increase in revenue from its main product, the Phlegm-Heat Clearing series, which has established a strong brand presence since its launch[94]. - The total comprehensive income for the period was CNY 239,439,876.43, compared to CNY 191,192,876.91 in the previous period, showing an increase of about 25.3%[189]. Cash Flow and Investments - The net cash flow from operating activities increased by 32.13% to ¥179,156,086.88, compared to ¥135,594,349.20 in the same period last year[20]. - The net increase in cash and cash equivalents was ¥229,601,609.76, a significant rise of 6,348.63%, driven by increased sales and recovered investments[56]. - The cash flow from investing activities was negative at ¥113,205,522.88, a decline of 241.83% due to increased maturity of time deposits[56]. - The company has committed to investing RMB 28,700 million in the "Modernization of Traditional Chinese Medicine and Pharmaceutical Products" project, with 100% completion[76]. - The company has utilized RMB 20,700.00 million for the first phase of the "Modernization of Traditional Chinese Medicine" project[72]. Research and Development - The company has established a joint R&D center with Shanghai Jiao Tong University to enhance collaboration in technology development and product innovation[29]. - The company is committed to R&D investment, with ongoing projects aimed at developing core product series and introducing new products[44]. - Research and development expenses increased to CNY 59,420,486.65, up 138.0% from CNY 24,926,996.65 in the previous year[174]. - The company is focusing on improving its R&D capabilities through various collaborative approaches to mitigate risks associated with new drug development[96]. - The company is advancing the clinical trial of its new product YKRH00020 inhalation solution, which has received a clinical trial notification[44]. Market Strategy and Expansion - The company maintains a comprehensive pharmaceutical business model, focusing on modern traditional Chinese medicine research, production, and sales, with no changes in its main business during the reporting period[28]. - The company’s sales strategy includes a professional academic promotion team to enhance product understanding and market penetration, supported by a comprehensive sales network across various regions[35]. - The company is focusing on market expansion by optimizing channels and exploring new markets, enhancing brand competitiveness[44]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings[189]. - The company plans to expand its market presence by launching new products in the second half of 2023[191]. Risk Management and Compliance - The company emphasizes the importance of risk management and has outlined potential risks and countermeasures in the report[3]. - The company is actively managing risks associated with policy changes in the pharmaceutical industry, including stricter regulations and cost control measures[93]. - The company is committed to complying with environmental regulations and standards relevant to its operations[107]. - The company has established an environmental self-monitoring plan in accordance with its discharge permit requirements[114]. - The company has not engaged in high-risk investments such as securities investments in the past twelve months[80]. Corporate Governance and Shareholder Information - The company has maintained a stable management team with no changes in directors or senior management during the reporting period[102]. - The integrity status of the company and its controlling shareholders remains good, with no significant debts due that have not been settled[126]. - The total number of shares held by the top 10 unrestricted shareholders includes significant holdings by Mu Jingwei and Zhang Yanqi, indicating concentrated ownership[152]. - The report does not mention any preferred shares or bond-related situations during the reporting period[159][162]. - The company has not reported any major contracts that would significantly impact its profit during the reporting period[140].

上海凯宝药业股份有限公司 独立董事对公司相关事项的独立意见 根据《关于在上市公司建立独立董事制度的指导意见》、《深圳证券交易所创 业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》、《公司章程》和《独立董事工作制度》的有关规定，我们作 为上海凯宝药业股份有限公司（以下简称"公司"）第五届董事会的独立董事，基 于独立判断的立场，对公司第五届董事会第十三次会议审议的相关事项进行了认真 审议并发表如下独立意见： 一、关于公司 2023 年半年度控股股东及其他关联方资金占用和对外担保的独 立意见 报告期内（自 2023 年 1 月 1 日至 2023 年 6 月 30 日），公司不存在控股股东及 其他关联方占用及变相占用公司资金的情况。 报告期内（自 2023 年 1 月 1 日至 2023 年 6 月 30 日），公司不存在为股东、股 东控股的子公司、股东的附属企业及其他关联方、任何非法人单位或个人提供担保 的情况；截至 2023 年 6 月 30 日，公司的对外担保总额为零。 二、关于 2023 年半年度关联交易事项的独立意见 公司全资子公司上海凯宝新谊（新乡）药业有 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2023-031 上海凯宝药业股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 表决结果：同意 9 票、反对 0 票、弃权 0 票。 二、审议通过了《2023 年半年度募集资金存放与使用情况的专项报告》的议案 2023 年半年度公司募集资金的存放与使用符合中国证监会、深圳证券交易所关 于上市公司募集资金存放与使用的相关规定，不存在募集资金存放与使用违规的情 形。《2023 年半年度募集资金存放与使用情况的专项报告》已由监事会发表了审核 意见，独立董事就此议案发表了明确同意的意见。 具体内容详见中国证监会指定的创业板信息披露网站上的相关公告。 表决结果：同意 9 票、反对 0 票、弃权 0 票。 特此公告。 上海凯宝药业股份有限公司董事会 上海凯宝药业股份有限公司（以下简称"公司"）第五届董事会第十三次会议 通知于 2023 年 7 月 28 日以邮件、书面的方式送达全体董事。会议于 2023 年 8 ...

上海凯宝药业股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》及相关格式指引的规定，上海凯宝药业股份有限公司（以下简称"公司"或"本 公司"）董事会编制了 2023 年半年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会以证监许可[2009]1387 号文核准，并经深圳证券交易 所同意，公司由主承销商东吴证券有限责任公司采用网下向配售对象询价配售与网上 向社会公众投资者定价发行相结合的方式，向社会公开发行人民币普通股（A 股）股票 2,740 万股，每股发行价 38.00 元，共募集资金总额为 104,120 万元，扣除承销费和保 荐费 5,726.60 万元后的募集资金为 98,393.4 万元，扣除其他发行费用 1,017.64 万元 后，募集资金净额 97,375.76 万元。 公司对募集资金采取了专户存储制度，上述募集资金已由主承销商东吴证券有限 责任公司于 2009 年 12 月 29 日汇入公司开立在中国建设银行上海柘林支行账号为 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2023-033 上海凯宝药业股份有限公司 关于独立董事姓名变更的公告 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"）董事会于近日收到公司独立 董事李整妮女士的通知，其提出的更名申请已获得审批通过并办理了新的居民身份 证，原姓名"李整妮"变更为"李珍妮"。 上述事项变更对公司经营活动不构成影响。公司独立董事不发生变化。 2023 年 8 月 8 日 上海凯宝药业股份有限公司 董事会 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2023-032 上海凯宝药业股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司(以下简称"公司")第五届监事会第十一次会议通 知于 2023 年 7 月 28 日以邮件方式送达全体监事。会议于 2023 年 8 月 8 日上午在公 司会议室以现场和通讯相结合的方式召开，会议应参会监事三名，实际参会监事三 名。本次会议的召集、召开符合《公司法》、《公司章程》、《公司监事会议事规 则》的有关规定。会议由监事会主席主持，经全体监事审议表决，通过了以下议案： 一、审议通过了《2023 年半年度报告》及《2023 年半年度报告摘要》 经全体监事认真核查认为：《2023 年半年度报告》及《2023 年半年度报告摘要》 的编制和审核程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整的反映了公司 2023 年半年度经营的实际情况，不存在虚假记载、误导性陈述或 者重大遗漏。 《2023 年半年度报告》及《2023 年半年度报告摘要》详见 ...

| 参与单位名称及 人员姓名 | 参与公司 2022 年度业绩说明会的广大投资者。 | | --- | --- | | 时 间 | 2023 年 4 月 26 日 下午 15:00-17：00 | | 地 点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | 上市公司接待人 | 董事长穆竟伟女士、总经理王国明先生、独立董事李整妮女士、董事会 | | 员姓名 | 秘书任立旺先生、财务总监张育琴女士 一、本次活动介绍 | | | 公司于 2023 年 4 月 26 日（星期三）下午 15 点至 17 点在全景网举 行 2022 年度业绩说明会。本次年度业绩说明会采用网络远程的方式举 | | | 行。投资者就公司未来发展、生产经营情况等方面进行了问答互动交流， 主要内容如下： | | 投资者关系活动 | 二、互动交流 | | | 1、穆董，我想了解一下，为什么优欣定的研发，凯宝到目前为止 | | 主要内容介绍 | 才使用了 1500 万的资金投入？是遇到什么困难了吗？ | | | 投资者您好，该项目按照研发时间节点正在进行中，感谢您的关注！ | | | 2、极泽的业绩是否符合并入公司财 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥459,387,490.40, representing a 33.61% increase compared to ¥343,817,802.76 in the same period last year[5] - The net profit attributable to shareholders for Q1 2023 was ¥80,178,876.36, a 39.11% increase from ¥57,636,350.93 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥74,483,881.60, reflecting a 30.24% increase compared to ¥57,190,694.89 in the previous year[5] - The basic earnings per share for Q1 2023 was ¥0.0767, up 39.20% from ¥0.0551 in the same quarter last year[5] - Total operating revenue for Q1 2023 reached ¥459,387,490.40, an increase of 33.7% compared to ¥343,817,802.76 in the same period last year[22] - Net profit for Q1 2023 was ¥80,118,147.25, representing a 40.2% increase from ¥57,142,663.02 in Q1 2022[23] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥353,887,256.07, compared to ¥165,979,475.93 in Q1 2022, indicating a significant increase of about 113.1%[24] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to ¥4,757,637,196.49, an increase of 11.70% from ¥4,259,271,286.92 at the end of the previous year[5] - Total liabilities reached ¥642,779,893.90, compared to ¥498,240,511.29 at the start of the year, an increase of 29.0%[20] - The company's equity attributable to shareholders rose to ¥4,115,640,086.51 from ¥3,761,752,830.44, an increase of 9.4%[20] Cash Flow - The company's cash flow from operating activities for Q1 2023 was ¥79,310,976.85, down 8.90% from ¥87,056,121.17 in the same period last year[5] - Cash inflows from operating activities totaled ¥485,001,700.80 in Q1 2023, compared to ¥427,893,178.34 in Q1 2022, marking an increase of about 13.3%[27] - The net cash flow from operating activities for Q1 2023 was ¥79,310,976.85, a decrease from ¥87,056,121.17 in Q1 2022, representing a decline of approximately 8.0%[27] - The net cash flow from investment activities increased by 350.96% compared to the same period last year, primarily due to a reduction in the purchase of financial products[13] - The net cash flow from financing activities decreased by 100.00% compared to the same period last year, mainly due to a reduction in cash inflows from financing activities[13] - The net increase in cash and cash equivalents grew by 2115.61% compared to the same period last year, attributed to a decrease in cash outflows from investment activities[13] - The total cash and cash equivalents at the end of Q1 2023 reached ¥582,156,672.45, up from ¥287,816,363.17 at the end of Q1 2022, reflecting an increase of approximately 102.2%[27] Research and Development - Research and development expenses increased by 140.34% year-on-year, indicating a significant investment in new product development[11] - Research and development expenses increased significantly to ¥24,076,351.54, compared to ¥10,017,656.02 in the previous year, reflecting a growth of 140.1%[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 79,143, with no preferred shareholders having restored voting rights[13] - The top three shareholders hold a combined 38.93% of the total shares, with Mu Jingwei holding 16.06%, Zhang Yanqi holding 15.37%, and Xinxiang Kaiyi Industrial Co., Ltd. holding 7.50%[13] - The total number of restricted shares at the end of the period is 129,152,731, all of which are subject to executive lock-up[16] Subsidiaries - The company established two new subsidiaries: Henan Yishen Pharmaceutical Chemical Co., Ltd. with a registered capital of RMB 20 million and Henan Kaibao Pharmaceutical Co., Ltd. with a registered capital of RMB 1 million[17] - The company holds 90% of the shares in Henan Yishen Pharmaceutical Chemical Co., Ltd., which was registered on February 28, 2023[17] - The company holds 100% of the shares in Henan Kaibao Pharmaceutical Co., Ltd., which obtained its pharmaceutical business license on March 29, 2023[17] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 8.98%, up from 5.31% in the same period last year, indicating improved profitability[5] - The company experienced a 75.55% increase in accounts payable, primarily due to increased material and other payables[11] - Total operating costs amounted to ¥364,517,922.48, up 35% from ¥270,153,211.19 in Q1 2022[23] - The company reported a significant increase in sales expenses, which totaled ¥236,460,016.10, compared to ¥179,111,174.54 in the previous year, reflecting a growth of 32.1%[23] - Cash and cash equivalents at the end of Q1 2023 were ¥715,115,006.57, up from ¥694,690,170.16 at the beginning of the year, indicating a growth of 2.0%[20] Audit Status - The report for Q1 2023 was not audited[28]

Financial Performance - The company's operating revenue for 2022 was ¥1,118,850,525.24, representing a 1.66% increase compared to ¥1,100,578,391.34 in 2021[19]. - The net profit attributable to shareholders for 2022 was ¥190,804,507.54, a 36.18% increase from ¥140,113,625.43 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥177,594,537.24, up 41.02% from ¥125,934,898.50 in 2021[19]. - The net cash flow from operating activities increased by 198.56% to ¥376,418,583.05 from ¥126,078,156.45 in 2021[19]. - Basic earnings per share for 2022 were ¥0.1824, a 36.12% increase from ¥0.1340 in 2021[19]. - Total assets at the end of 2022 were ¥4,259,271,286.92, a 26.92% increase from ¥3,355,816,769.77 at the end of 2021[19]. - The net assets attributable to shareholders at the end of 2022 were ¥3,761,752,830.44, reflecting a 23.54% increase from ¥3,044,914,136.88 in 2021[19]. - The weighted average return on equity for 2022 was 20.69%, an increase of 2.98% from 17.71% in 2021[19]. - The company reported a significant increase in quarterly revenues, with Q4 2022 revenue reaching ¥318,837,460.39[21]. - The company's cash generated from operating activities for 2022 was ¥87,056,121.17, compared to ¥48,538,228.03 in 2021, indicating a significant increase[22]. Product and Market Development - The company’s main product, Tanreqing injection, is recognized as a key medication in the treatment of various major infectious diseases, including COVID-19[34]. - The company has established three major product lines: respiratory, cardiovascular, and digestive fields, with key products including Tanreqing injection/capsule and Qishen capsule[35]. - The subsidiary Kaibao Health focuses on product development and market promotion in the health technology sector, leveraging traditional Chinese medicine[36]. - The company has established a strong competitive edge in the respiratory system medication market, particularly during the COVID-19 pandemic[34]. - The company is actively exploring new markets and product applications, including the development of new food raw materials like "in vitro cultivated bear bile powder"[44]. - The company has initiated an expansion and automation upgrade of its extraction production line to enhance capacity and ensure market supply[44]. Research and Development - Continuous R&D efforts are being made for the main product Tanreqing, including clinical evidence and real-world data studies to support academic promotion[44]. - The company has established a joint R&D center with Shanghai Jiao Tong University to enhance technology development and product innovation[36]. - The company is committed to enhancing its research and development capabilities in response to national policies promoting traditional Chinese medicine[30][32]. - The company is focusing on R&D innovation, increasing investment in research and development to enhance core competitiveness and achieve significant progress in core product series development[46]. - The Phlegm-Heat Clearing series products are undergoing various clinical trials, with the Phlegm-Heat Clearing Oral Liquid in Phase III clinical research and the Phlegm-Heat Clearing Capsule in Phase II clinical research[47]. Corporate Governance and Compliance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and enhancing information disclosure practices[114]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure[117]. - The company has established a performance evaluation and incentive mechanism for senior management, linking compensation directly to performance[121]. - The internal audit department is responsible for overseeing financial reporting and internal controls, ensuring the safety and integrity of company assets[124]. - The company maintains independence from its controlling shareholder in operations, finance, and management, ensuring autonomous business capabilities[126]. - The company has implemented a comprehensive internal control system to mitigate risks and enhance operational efficiency[124]. Environmental and Social Responsibility - The company has established two wastewater treatment facilities with a processing capacity of 1,000 tons per day to ensure stable compliance with discharge standards[179]. - The company invested CNY 585,400 in environmental governance and protection in 2022, and paid CNY 27,800 in environmental protection tax[186]. - The company donated a total of CNY 1,500,000 to various charitable organizations and local communities during the reporting period[187][188]. - The company actively participates in poverty alleviation and rural revitalization projects, supporting education and infrastructure development in targeted areas[189]. - The company has developed emergency response plans for environmental incidents, including hazardous chemical accidents and abnormal operating conditions[184]. Financial Management and Investment - The company plans to use RMB 78,145,870 of the raised funds, including RMB 14 million for permanent working capital and RMB 18,305,000 for the modernization of traditional Chinese medicine products[85]. - The company reported a total of RMB 1,439,490,000 in financial assets at the end of the period, with significant changes in fair value[78]. - The company has not engaged in derivative investments during the reporting period[83]. - The company’s total financial liabilities remained at zero, indicating no debt obligations[78]. - The company has not sold any significant assets during the reporting period[101]. Employee Management and Development - The total number of employees at the end of the reporting period is 1,380, with 507 in the parent company and 873 in major subsidiaries[159]. - The company has established a competitive compensation system based on market principles, including fixed salaries, performance bonuses, and comprehensive welfare benefits[160]. - The company plans to enhance employee training in 2023, focusing on sales, knowledge skills, and management training to improve overall capabilities[161]. - The company has implemented a training system to foster a learning-oriented environment, enhancing employee skills and knowledge[161]. Future Outlook and Strategy - The company aims to enhance its core product technology innovation and quality, focusing on the modernization of traditional Chinese medicine as a long-term development direction[104]. - In 2023, the company plans to strengthen quality control and risk management, aiming for "zero defects" in product sampling and improving operational efficiency through information technology[105]. - The company will optimize market promotion by innovating academic promotion methods and expanding product market development and application[106]. - The company faces industry policy risks due to ongoing healthcare reforms, which may impact the pharmaceutical sector significantly[108].